Jorge Bartual Bardisa, Carolina Vizcaíno Díaz, María Jesús Ferrández Berenguer
{"title":"Does early surfactant improve outcome in late preterm newborn? Retrospective study in a neonatal intensive care unit.","authors":"Jorge Bartual Bardisa, Carolina Vizcaíno Díaz, María Jesús Ferrández Berenguer","doi":"10.1016/j.medine.2025.502161","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To compare the early administration of surfactant, before 12 h of life, versus late, in late preterm neonates (born between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation), with moderate-severe respiratory distress.</p><p><strong>Design: </strong>Retrospective, observational, analytical, case-control study, with late preterm infants admitted between 2012-2021. It is divided into 2 groups: surfactant administered ≤ 12 h of life and >12 h and evolution is compared using univariate analysis.</p><p><strong>Setting: </strong>Neonatal Intensive Care Unit (NICU) level III of a Universitary Hospital.</p><p><strong>Patients or participants: </strong>57 patients, 30 in the early group and 27 in the late group.</p><p><strong>Inclusion criteria: </strong>neonates from 34<sup>+0</sup> to 36<sup>+6</sup> weeks of gestation, with respiratory distress syndrome, in need of non-invasive ventilation and surfactant.</p><p><strong>Interventions: </strong>None.</p><p><strong>Main variables of interest: </strong>Sociodemographic, clinical and evolutionary: redosing, duration of respiratory support, oxygen and time to stop requiring it after surfactant. Also, complications and length of hospitalization.</p><p><strong>Results: </strong>In the early group there was less need for redosing (3.3% vs 48.1%, P < .001) and a decrease in duration, in days, of stay in the NICU (7 vs 10.5, P .002), invasive mechanical ventilation (2.4 vs 3.9, P .034), total respiratory support (4.6 vs 6.6, P .005) and oxygen therapy (0.4 vs 2.8, P < .001). Also, lower incidence of pneumothorax (0% vs 33.3%, P .001). Furthermore, 12 h after administration, 83.4% maintained FiO2 0.21, compared to 44.4% in the late administration.</p><p><strong>Conclusions: </strong>In our study, early administration in late preterm infants provides benefits in terms of respiratory assistance and complications. We suggest expanding studies to establish recommendations in this group of patients.</p>","PeriodicalId":94139,"journal":{"name":"Medicina intensiva","volume":" ","pages":"502161"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina intensiva","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medine.2025.502161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To compare the early administration of surfactant, before 12 h of life, versus late, in late preterm neonates (born between 34+0 and 36+6 weeks of gestation), with moderate-severe respiratory distress.
Design: Retrospective, observational, analytical, case-control study, with late preterm infants admitted between 2012-2021. It is divided into 2 groups: surfactant administered ≤ 12 h of life and >12 h and evolution is compared using univariate analysis.
Setting: Neonatal Intensive Care Unit (NICU) level III of a Universitary Hospital.
Patients or participants: 57 patients, 30 in the early group and 27 in the late group.
Inclusion criteria: neonates from 34+0 to 36+6 weeks of gestation, with respiratory distress syndrome, in need of non-invasive ventilation and surfactant.
Interventions: None.
Main variables of interest: Sociodemographic, clinical and evolutionary: redosing, duration of respiratory support, oxygen and time to stop requiring it after surfactant. Also, complications and length of hospitalization.
Results: In the early group there was less need for redosing (3.3% vs 48.1%, P < .001) and a decrease in duration, in days, of stay in the NICU (7 vs 10.5, P .002), invasive mechanical ventilation (2.4 vs 3.9, P .034), total respiratory support (4.6 vs 6.6, P .005) and oxygen therapy (0.4 vs 2.8, P < .001). Also, lower incidence of pneumothorax (0% vs 33.3%, P .001). Furthermore, 12 h after administration, 83.4% maintained FiO2 0.21, compared to 44.4% in the late administration.
Conclusions: In our study, early administration in late preterm infants provides benefits in terms of respiratory assistance and complications. We suggest expanding studies to establish recommendations in this group of patients.